These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3916851)

  • 1. Corneal penetration and ocular bioavailability of drugs.
    Burstein NL; Anderson JA
    J Ocul Pharmacol; 1985; 1(3):309-26. PubMed ID: 3916851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limits on optimizing ocular drug delivery.
    Keister JC; Cooper ER; Missel PJ; Lang JC; Hager DF
    J Pharm Sci; 1991 Jan; 80(1):50-3. PubMed ID: 2013850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular preparations: the formulation approach.
    Kaur IP; Kanwar M
    Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biological availability of ophthalmic drugs. 1. Increasing drug permeability in the cornea].
    Masteiková R; Chalupová Z; Savickiene N
    Ceska Slov Farm; 2004 Mar; 53(2):73-9. PubMed ID: 15095575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transcorneal drug delivery: prospects for the use of liposomes].
    Aliautdin RN; Iezhitsa IN; Agarval R
    Vestn Oftalmol; 2014; 130(4):117-22. PubMed ID: 25306734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses.
    Gause S; Hsu KH; Shafor C; Dixon P; Powell KC; Chauhan A
    Adv Colloid Interface Sci; 2016 Jul; 233():139-154. PubMed ID: 26318359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery.
    Kaur IP; Smitha R
    Drug Dev Ind Pharm; 2002 Apr; 28(4):353-69. PubMed ID: 12056529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomes in topical ophthalmic drug delivery: an update.
    Agarwal R; Iezhitsa I; Agarwal P; Abdul Nasir NA; Razali N; Alyautdin R; Ismail NM
    Drug Deliv; 2016 May; 23(4):1075-91. PubMed ID: 25116511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of various concentrations of terpene-4-ol enhancer and carbopol-934 mucoadhesive upon the in vitro ocular transport and the in vivo intraocular pressure lowering effects of dorzolamide ophthalmic formulations using albino rabbits.
    Afouna MI; Khedr A; Abdel-Naim AB; Al-Marzoqi A
    J Pharm Sci; 2010 Jan; 99(1):119-27. PubMed ID: 19530071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Approaches for Increasing Ophthalmic Bioavailability for Eye Drop Formulations.
    Lanier OL; Manfre MG; Bailey C; Liu Z; Sparks Z; Kulkarni S; Chauhan A
    AAPS PharmSciTech; 2021 Mar; 22(3):107. PubMed ID: 33719019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular tolerance of absorption enhancers in ophthalmic preparations.
    Furrer P; Mayer JM; Plazonnet B; Gurny R
    AAPS PharmSci; 2002; 4(1):E2. PubMed ID: 12049486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations.
    Fernández-Ferreiro A; Silva-Rodríguez J; Otero-Espinar FJ; González-Barcia M; Lamas MJ; Ruibal A; Luaces-Rodriguez A; Vieites-Prado A; Sobrino T; Herranz M; García-Varela L; Blanco-Mendez J; Gil-Martínez M; Pardo M; Moscoso A; Medín-Aguerre S; Pardo-Montero J; Aguiar P
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):772-780. PubMed ID: 28146242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
    Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
    Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for evaluation of topical ophthalmic drug products in different compartments of fresh eye tissues in a rabbit model.
    Chockalingam A; Xu L; Stewart S; LeMerdy M; Tsakalozou E; Fan J; Patel V; Rouse R
    J Pharmacol Toxicol Methods; 2019; 96():9-14. PubMed ID: 30552958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bioavailability of drugs applied to the eye externally].
    Sieradzki E
    Klin Oczna; 1991 Jan; 93(1):34-6. PubMed ID: 2046287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
    Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs.
    Agarwal P; Scherer D; Günther B; Rupenthal ID
    Int J Pharm; 2018 Mar; 538(1-2):119-129. PubMed ID: 29339249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
    Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
    Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ophthalmic preservatives as absorption promoters for ocular drug delivery.
    Sasaki H; Nagano T; Yamamura K; Nishida K; Nakamura J
    J Pharm Pharmacol; 1995 Sep; 47(9):703-7. PubMed ID: 8583378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular drug bioavailability from topically applied liposomes.
    Lee VH; Urrea PT; Smith RE; Schanzlin DJ
    Surv Ophthalmol; 1985; 29(5):335-48. PubMed ID: 3992472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.